DGX Quest Diagnostics
Data as of close
Healthcare · Services-Medical Laboratories
Quest Diagnostics (DGX) is a healthcare company in the Services-Medical Laboratories industry, with a market capitalization of $27.6 billion. Shares last traded at $250.75, near their 52-week high. Over the past year the stock is up 42.6%. DGX trades at a price-to-earnings ratio of 24.44, below the Services-Medical Laboratories median of 34.77. Net profit margin is 9.5%, above the peer median of -5.4%. Revenue grew 11.8% year over year. The shares yield 1.3% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.
DGX Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $353M | $3.12 | 36% |
| 2024-12-31 | $331M | $2.93 | 38% |
| 2023-12-31 | $314M | $2.78 | 37% |
| 2022-12-31 | $305M | $2.58 | 32% |
| 2021-12-31 | $309M | $2.41 | 15% |
| 2020-12-31 | $297M | $2.18 | 21% |
| 2019-12-31 | $286M | $2.10 | 33% |
| 2018-12-31 | $266M | $1.91 | 36% |
| 2017-12-31 | $247M | $1.76 | 32% |
| 2016-12-31 | $223M | $1.57 | 35% |
| 2015-12-31 | $212M | $1.46 | 30% |
| 2014-12-31 | $187M | $1.29 | 34% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q3 2026 | $2.78 | 2026-10-23 |
| Q2 2026 | $2.84 | 2026-07-23 |
| Q1 2026 | $2.24 | 2026-04-22 |
| Q4 2025 (derived) | $2.18 | 2026-02-26 |
| FY 2025 | $8.75 | 2026-02-26 |
| Q3 2025 | $2.16 | 2025-10-21 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Services-Medical Laboratories peers
DGX vs 14 industry peers (Services-Medical Laboratories), by market cap. Data as of close
| NTRA | Natera, Inc. | $54.6B | — | 20.18 | -7.1% | -8.49% |
| LH | Labcorp | $28.9B | 28.77 | 1.98 | 6.9% | -1.65% |
| DGX | Quest Diagnostics | $27.6B | 24.44 | 2.33 | 9.5% | -0.44% |
| GH | Guardant Health, Inc. | $22.9B | — | 19.38 | -38.3% | -4.45% |
| CAI | Caris Life Sciences, Inc. | $9.1B | 86.26 | 9.16 | 10.6% | -6.50% |
| GRAL | Grail, Inc. | $6.0B | — | — | — | -6.79% |
| RDNT | Radnet, Inc. | $5.8B | — | 2.54 | -0.9% | -0.54% |
| BLLN | Billiontoone, Inc. | $5.2B | 138.09 | 13.10 | 9.5% | -2.52% |
| CDNA | Caredx, Inc. | $4.5B | 35.08 | 9.07 | 25.9% | -1.68% |
| VCYT | Veracyte, Inc. | $3.9B | 34.45 | 7.02 | 20.4% | -1.87% |
| CELC | Celcuity Inc. | $3.3B | — | — | — | -2.90% |
| FTRE | Fortrea Holdings Inc. | $1.9B | — | 0.72 | -2.6% | -5.99% |
| PSNL | Personalis, Inc. | $1.7B | — | — | — | -0.44% |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | — | — | — | -2.32% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.